Virus-like particles presenting interleukin-33 molecules: Immunization characteristics and potentials of blocking IL-33/ST2 pathway in allergic airway inflammation

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 8, 2014, Pages 2303-2311

  Long, Qiong ^a   Huang, Weiwei ^a   Yao, Yufeng ^a   Yang, Xu ^a   Sun, Wenjia ^a   Jin, Xiaomei ^a   Li, Yang ^a   Chu, Xiaojie ^a   Liu, Cunbao ^a   Peng, Zhikang ^b   Ma, Yanbing ^a  

^a INSTITUTE OF MEDICAL BIOLOGY   (China)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Animal model; Asthma; Cytokine; Inflammation; Interleukin (IL) 33; Vaccine; Virus like particles (VLPs)

Indexed keywords

CHIMERIC PROTEIN; EPITOPE; HEPATITIS B CORE ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 33; INTERLEUKIN 33 VACCINE; OVALBUMIN; UNCLASSIFIED DRUG; VACCINE; IL1RL1 PROTEIN, MOUSE; INTERLEUKIN DERIVATIVE; INTERLEUKIN RECEPTOR; INTERLEUKIN-33, MOUSE; VIROSOME; VIRUS LIKE PARTICLE VACCINE;

ALLERGIC AIRWAY INFLAMMATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; CELL HYPERPLASIA; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC RECOMBINATION; GOBLET CELL; HISTOPATHOLOGY; IMMUNIZATION; INFLAMMATORY CELL; LUNG PARENCHYMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL; VACCINATION; VIRUS LIKE AGENT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ANIMALS; ASTHMA; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INTERLEUKINS; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; RECEPTORS, INTERLEUKIN; SIGNAL TRANSDUCTION; VACCINES, VIRUS-LIKE PARTICLE; VIROSOMES;

EID: 84908388688     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29425     Document Type: Article

References (43)

1. Grotenboer NS, Ketelaar ME, Koppelman GH, Nawijn MC. Decoding asthma: translating genetic variation in IL33 and IL1RL1 into disease pathophysiology. J Allergy Clin Immunol 2013; 131:856-65; PMID:23380221; http://dx.doi.org/10.1016/j.jaci.2012.11.028
2. Préfontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, Lemière C, Martin JG, Hamid Q. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009; 183:5094-103; PMID:19801525; http://dx.doi.org/10.4049/jimmunol.0802387
3. Kondo Y, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Morimoto M, Hayashi N, Hoshino T, Fujimoto J, Nakanishi K. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 2008; 20:791-800; PMID:18448455; http://dx.doi.org/10.1093/intimm/dxn037
4. Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY. IL-33 exacerbates eosinophil-mediated airway inf lammation. J Immunol 2010; 185:3472-80; PMID:20693421; http://dx.doi.org/10.4049/jimmunol.1000730
5. Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, Ying S, Pitman N, Mirchandani A, Rana B, van Rooijen N, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inf lammation. J Immunol 2009; 183:6469-77; PMID:19841166; http://dx.doi.org/10.4049/jimmunol.0901575
6. Barlow JL, Peel S, Fox J, Panova V, Hardman CS, Camelo A, Bucks C, Wu X, Kane CM, Neill DR, et al. IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction. J Allergy Clin Immunol 2013; 132:933-41; PMID:23810766; http://dx.doi.org/10.1016/j.jaci.2013.05.012
7. Yin H, Li XY, Liu T, Yuan BH, Zhang BB, Hu SL, Gu HB, Jin XB, Zhu JY. Adenovirus-mediated delivery of soluble ST2 attenuates ovalbumin-induced allergic asthma in mice. Clin Exp Immunol 2012; 170:1-9; PMID:22943195; http://dx.doi.org/10.1111/j.1365-2249.2012.04629.x
8. Mizutani N, Nabe T, Yoshino S. Interleukin-33 and alveolar macrophages contribute to the mechanisms underlying the exacerbation of IgE-mediated airway inf lammation and remodelling in mice. Immunology 2013; 139:205-18; PMID:23323935; http://dx.doi.org/10.1111/imm.12071
9. Kim HY, Chang YJ, Subramanian S, Lee HH, Albacker LA, Matangkasombut P, Savage PB, McKenzie AN, Smith DE, Rottman JB, et al. Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity. J Allergy Clin Immunol 2012; 129:216-27, e1-6; PMID:22119406; http://dx.doi.org/10.1016/j.jaci.2011.10.036
10. Saglani S, Lui S, Ullmann N, Campbell GA, Sherburn RT, Mathie SA, Denney L, Bossley CJ, Oates T, Walker SA, et al. IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma. J Allergy Clin Immunol 2013; 132:676-85, e13; PMID:23759184; http://dx.doi.org/10.1016/j.jaci.2013.04.012
11. Delavallée L, Duvallet E, Semerano L, Assier E, Boissier MC. Anti-cytokine vaccination in autoimmune diseases. Swiss Med Wkly 2010; 140:w13108; PMID:21043003
12. Lee CK, Kim HS, Ye BD, Lee KM, Kim YS, Rhee SY, Kim HJ, Yang SK, Moon W, Koo JS, et al.; Korean Association for the Study of Intestinal Diseases (KASID) Study. Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. J Crohns Colitis 2014; 8:384-91; PMID:24144611; http://dx.doi.org/10.1016/j.crohns.2013.09.022
13. Ma Y, Halayko AJ, Basu S, Guan Q, Weiss CR, Ma AG, HayGlass KT, Becker AB, Warrington RJ, Peng Z. Sustained suppression of IL-13 by a vaccine attenuates airway inf lammation and remodeling in mice. Am J Respir Cell Mol Biol 2013; 48:540-9; PMID:23470628; http://dx.doi.org/10.1165/rcmb.2012-0060OC
14. Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, Jiang X, Jetten AM, Khoury SJ, Fuhlbrigge RC, Kuchroo VK, et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012; 18:1248-53; PMID:22772464; http://dx.doi.org/10.1038/nm.2856
15. Guler R, Parihar SP, Spohn G, Johansen P, Brombacher F, Bachmann MF. Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine 2011; 29: 1339-46; PMID:21093494; http://dx.doi.org/10.1016/j.vaccine.2010.10.045
16. Guan Q, Weiss CR, Qing G, Ma Y, Peng Z. An IL-17 peptide-based and virus-like particle vaccine enhances the bioactivity of IL-17 in vitro and in vivo. Immunotherapy 2012; 4:1799-807; PMID:23240747; http://dx.doi.org/10.2217/imt.12.129
17. Roseman AM, Borschukova O, Berriman JA, Wynne SA, Pumpens P, Crowther RA. Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies. J Mol Biol 2012; 423:63-78; PMID:22750730; http://dx.doi.org/10.1016/j.jmb.2012.06.032
18. Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, Coyle AJ, Koike M, Spitalny GL, Kiener PA, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010; 125:1237-44, e2; PMID:20513521; http://dx.doi.org/10.1016/j.jaci.2010.04.005
19. Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE, Deschesnes F, Duong M, Durn BL, Howie KJ, et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011; 183:1007-14; PMID:21057005; http://dx.doi.org/10.1164/rccm.201008-1210OC
20. Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187:804-11; PMID:23471469; http://dx.doi.org/10.1164/rccm.201208-1414OC
21. Doherty TA, Soroosh P, Khorram N, Fukuyama S, Rosenthal P, Cho JY, Norris PS, Choi H, Scheu S, Pfeffer K, et al. The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling. Nat Med 2011; 17:596-603; PMID:21499267; http://dx.doi.org/10.1038/nm.2356
22. Hardyman MA, Wilkinson E, Martin E, Jayasekera NP, Blume C, Swindle EJ, Gozzard N, Holgate ST, Howarth PH, Davies DE, et al. TNF-α-mediated bronchial barrier disruption and regulation by src-family kinase activation. J Allergy Clin Immunol 2013; 132:665-75, e8; PMID:23632299; http://dx.doi.org/10.1016/j.jaci.2013.03.005
23. Hansbro PM, Scott GV, Essilfie AT, Kim RY, Starkey MR, Nguyen DH, Allen PD, Kaiko GE, Yang M, Horvat JC, et al. Th2 cytokine antagonists: potential treatments for severe asthma. Expert Opin Investig Drugs 2013; 22:49-69; PMID:23126660; http://dx.doi.org/10.1517/13543784.2013.732997
24. Ma Y, Guan Q, Bai A, Weiss CR, Hillman CL, Ma A, Zhou G, Qing G, Peng Z. Targeting TGF-beta1 by employing a vaccine ameliorates fibrosis in a mouse model of chronic colitis. Inflamm Bowel Dis 2010; 16:1040-50; PMID:19924805; http://dx.doi.org/10.1002/ibd.21167
25. Ma Y, HayGlass KT, Becker AB, Fan Y, Yang X, Basu S, Srinivasan G, Simons FE, Halayko AJ, Peng Z. Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am J Respir Crit Care Med 2007; 176:439-45; PMID:17556715; http://dx.doi.org/10.1164/rccm.200610-1405OC
26. Ma Y, Ma AG, Peng Z. A potential immunotherapy approach: mucosal immunization with an IL-13 peptide-based virus-like particle vaccine in a mouse asthma model. Vaccine 2007; 25:8091-9; PMID:17935839; http://dx.doi.org/10.1016/j.vaccine.2007.09.009
27. Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov 2013; 12:117-29; PMID:23334207; http://dx.doi.org/10.1038/nrd3838
28. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 2013; 13:9-22; PMID:23154224; http://dx.doi.org/10.1038/nri3341
29. Tachdjian R, Al Khatib S, Schwinglshackl A, Kim HS, Chen A, Blasioli J, Mathias C, Kim HY, Umetsu DT, Oettgen HC, et al. In vivo regulation of the allergic response by the IL-4 receptor alpha chain immunoreceptor tyrosine-based inhibitory motif. J Allergy Clin Immunol 2010; 125:1128-36, e8; PMID:20392476; http://dx.doi.org/10.1016/j.jaci.2010.01.054
30. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One 2008; 3:e3331; PMID:18836528; http://dx.doi.org/10.1371/journal.pone.0003331
31. Enoksson M, Lyberg K, Möller-Westerberg C, Fallon PG, Nilsson G, Lunderius-Andersson C. Mast cells as sensors of cell injury through IL-33 recognition. J Immunol 2011; 186:2523-8; PMID:21239713; http://dx.doi.org/10.4049/jimmunol.1003383
32. Enoksson M, Möller-Westerberg C, Wicher G, Fallon PG, Forsberg-Nilsson K, Lunderius-Andersson C, Nilsson G. Intraperitoneal influx of neutrophils in response to IL-33 is mast cell-dependent. Blood 2013; 121:530-6; PMID:23093619; http://dx.doi.org/10.1182/blood-2012-05-434209
33. Alves-Filho JC, Sônego F, Souto FO, Freitas A, Verri WA Jr., Auxiliadora-Martins M, Basile-Filho A, McKenzie AN, Xu D, Cunha FQ, et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med 2010; 16:708-12; PMID:20473304; http://dx.doi.org/10.1038/nm.2156
34. Guabiraba R, Besnard AG, Menezes GB, Secher T, Jabir MS, Amaral SS, Braun H, Lima-Junior RC, Ribeiro RA, Cunha FQ, et al. IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice. Mucosal Immunol 2014; (Forthcoming); PMID:24424522; http://dx.doi.org/10.1038/mi.2013.124
35. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007; 117:1538-49; PMID:17492053; http://dx.doi.org/10.1172/JCI30634
36. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, Lee RT. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009; 2:684-91; PMID:19919994; http://dx.doi.org/10.1161/CIRCHEARTFAILURE.109.873240
37. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, Baker AH, McInnes IB, Liew FY. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205:339-46; PMID:18268038; http://dx.doi.org/10.1084/jem.20071868
38. Saidi S, Bouri F, Lencel P, Duplomb L, Baud'huin M, Delplace S, Leterme D, Miellot F, Heymann D, Hardouin P, et al. IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. Cytokine 2011; 53:347-54; PMID:21190867; http://dx.doi.org/10.1016/j.cyto.2010.11.021
39. Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun 2009; 384:105-9; PMID:19393621; http://dx.doi.org/10.1016/j.bbrc.2009.04.081
40. Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN, Xu D, Sattar N, McInnes IB, Liew FY. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res 2010; 107:650-8; PMID:20634488; http://dx.doi.org/10.1161/CIRCRESAHA.110.218867
41. Link A, Bachmann MF. Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines. Immunotherapy 2010; 2:561-74; PMID:20636009; http://dx.doi.org/10.2217/imt.10.30
42. Le Buanec H, Bensussan A, Bagot M, Gallo RC, Zagury D. Active and passive anticytokine immune therapies: current status and development. Adv Immunol 2012; 115:187-227; PMID:22608260; http://dx.doi.org/10.1016/B978-0-12-394299-9.00007-2
43. Jennings GT, Bachmann MF. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol 2009; 49:303-26; PMID:18851703; http://dx.doi.org/10.1146/annurev-pharmtox-061008-103129